Home / ADIL : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ADIL make money? Does ADIL have pricing power? What's the Earnings Whisper? Will ADIL profit more as the business scales? What is ADIL's management track record? Is ADIL's current price justified?

Adial Pharmaceuticals, Inc.

$4.9 -$1.10 (-18.33%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

Day Range

$4.9$6.06

Year Range

$1.31$10.75

Market Cap

4.7M

AVG Volume

340.32K

Trailing/Forward PE

-0.3/-

PEG ratio

Dividend Yield

Next Earnings Date

2026-11-18

Primary Exchange

NASDAQ

Net Income (USD)

ADIL Net Income (USD) by year
Period	Net Income (USD)
2025	-7.98M
2024	-13.2M
2023	-5.12M
2022	-12.73M
2021	-19.42M
2020	-10.89M
2019	-8.59M
2018	-11.63M
2017	-1.14M
2016	-420.2K

Operating Income (USD)

ADIL Operating Income (USD) by year
Period	Operating Income (USD)
2025	-7.8M
2024	-8.28M
2023	-6.89M
2022	-11.45M
2021	-19.29M
2020	-10.93M
2019	-8.24M
2018	-6.99M
2017	-995.29K
2016	-410.81K

EBITDA (USD)

ADIL EBITDA (USD) by year
Period	EBITDA (USD)
2025	-7.98M
2024	-13.2M
2023	-7M
2022	-11.24M
2021	-17.98M
2020	-10.93M
2019	-8.21M
2018	-10.46M
2017	-994.35K
2016	-410.25K

Cash Flows (USD)

ADIL Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-6.49M
2024	-6.92M
2023	-3.69M
2022	-11.19M
2021	-12.01M
2020	-7.63M
2019	-6.34M
2018	-2.5M
2017	-494.86K
2016	-274.38K

EPS (USD)

ADIL EPS (USD) by year
Period	EPS (USD)
2025	-16.8
2024	-81.75
2023	-102.5
2022	-314.75
2021	-659
2020	-539.25
2019	-559.5
2018	-1263.25
2017	-137.25
2016	-55

Expenses (USD)

ADIL Expenses (USD) by year
Period	Expenses (USD)
2025	7.8M
2024	8.28M
2023	3.77M
2022	11.45M
2021	17.76M
2020	10.93M
2019	8.24M
2018	6.99M
2017	995.29K
2016	410.81K

Cash & Debt (USD)

ADIL Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	5.88M
2024	3.75M
2023	2.83M
2022	4M
2021	6.06M
2020	4.4M
2019	6.78M
2018	3.87M
2017	18.25K
2016	87.99K

Debt ratios

ADIL Debt ratios by year
Period	Debt ratios
2025	0.15
2024	0.08
2023	0.06
2022	0.08
2021	0.12
2020	0.14
2019	0.34

Return on Capital

ADIL Return on Capital by year
Period	Return on Capital
2025	-151.18%
2024	-324.41%
2023	-125.46%
2022	-388.57%
2021	-553.72%
2020	-273.28%
2019	-120.32%
2018	-261.89%
2017	114.23%
2016	406.02%

Shares Outstanding

ADIL Shares Outstanding by year
Period	Shares Outstanding
2025	1.11M
2024	743.55K
2023	66.54K
2022	42.7K
2021	32.85K
2020	23K
2019	16.98K
2018	10.62K
2017	8.76K
2016	7.65K

Book Value Per Share (USD)

ADIL Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	4.75
2024	5.47
2023	61.37
2022	76.73
2021	106.8
2020	173.28
2019	420.53
2018	418.01
2017	-113.88
2016	-13.53

Total Assets (USD)

ADIL Total Assets (USD) by year
Period	Total Assets (USD)
2025	6.8M
2024	5.04M
2023	4.74M
2022	5.73M
2021	7.63M
2020	5.49M
2019	7.68M
2018	4.7M
2017	34.55K
2016	151.53K

Employee Count

ADIL Employee Count by year
Period	Employee Count
2025	6
2024	7
2023	7
2022	20
2021	21
2020	9
2019	4
2018	6

Free Cash Flow Yield

ADIL Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-49.16%
Sep 26	-33.83%
Aug 26	-43.01%
Aug 26	-38.73%
Aug 26	-60.52%
Aug 26	-119.56%
Jul 26	-142.47%
Jul 26	-171.17%
Jul 26	-169.95%
Jul 26	-171.17%
Jul 26	-164.08%
Jun 26	-185.88%
Jun 26	-183.02%
Jun 26	-159.68%
Jun 26	-215.32%
May 26	-198.27%
May 26	-228.77%
May 26	-344.82%
May 26	-332.76%
May 26	-377.02%
Apr 26	-369.87%
Apr 26	-358.52%
Apr 26	-372.22%
Apr 26	-345.79%
Mar 26	-356.33%
Mar 26	-292.19%
Mar 26	-298.16%
Mar 26	-319.34%
Feb 26	-295.13%
Feb 26	-304.76%
Feb 26	-261.99%
Feb 26	-239.32%
Jan 26	-142.22%
Jan 26	-129.86%
Jan 26	-129.86%
Jan 26	-124.44%
Jan 26	-124.44%
Dec 25	-129.86%
Dec 25	-124.44%
Dec 25	-99.56%
Dec 25	-96.34%
Nov 25	-96.34%
Nov 25	-99.56%
Nov 25	-90.51%
Nov 25	-184.93%
Oct 25	-174.36%
Oct 25	-169.52%
Oct 25	-169.52%
Oct 25	-160.59%
Oct 25	-152.56%
Sep 25	-179.49%
Sep 25	-174.36%
Sep 25	-174.36%
Sep 25	-174.36%
Aug 25	-160.59%
Aug 25	-160.59%
Aug 25	-156.48%
Aug 25	-97.42%
Aug 25	-80.48%
Jul 25	-72.59%
Jul 25	-82.27%
Jul 25	-94.92%
Jul 25	-112.18%
Jun 25	-108.88%
Jun 25	-148.08%
Jun 25	-105.77%
Jun 25	-64.95%
May 25	-53.65%
May 25	-53.65%
May 25	-56.09%
May 25	-62.07%
May 25	-55.58%
Apr 25	-53.97%
Apr 25	-53.97%
Apr 25	-52.45%
Apr 25	-59.11%
Mar 25	-55.58%
Mar 25	-50.32%
Mar 25	-53.97%
Mar 25	-49.65%
Feb 25	-118.62%
Feb 25	-118.62%
Feb 25	-126.63%
Feb 25	-121.7%
Jan 25	-112.9%
Jan 25	-95.62%
Jan 25	-97.61%
Jan 25	-91.87%
Jan 25	-85.97%
Dec 24	-91.87%
Dec 24	-87.58%
Dec 24	-85.97%
Dec 24	-78.09%
Nov 24	-93.71%
Nov 24	-92.78%
Nov 24	-88.4%
Nov 24	-118.74%
Nov 24	-122.27%
Oct 24	-112.27%
Oct 24	-122.27%

Price to Book

ADIL Price to Book by year
Period	Price to Book
Sep 26	145.17
Sep 26	210.94
Aug 26	165.91
Aug 26	184.28
Aug 26	117.91
Aug 26	1.47
Jul 26	1.23
Jul 26	1.02
Jul 26	1.03
Jul 26	1.02
Jul 26	1.07
Jun 26	0.94
Jun 26	0.96
Jun 26	1.1
Jun 26	0.81
May 26	0.88
May 26	0.77
May 26	0.51
May 26	0.53
May 26	0.33
Apr 26	0.33
Apr 26	0.34
Apr 26	0.33
Apr 26	0.36
Mar 26	0.35
Mar 26	0.42
Mar 26	0.41
Mar 26	0.39
Feb 26	0.5
Feb 26	0.48
Feb 26	0.56
Feb 26	0.61
Jan 26	1.03
Jan 26	1.13
Jan 26	1.13
Jan 26	1.18
Jan 26	1.18
Dec 25	1.13
Dec 25	1.18
Dec 25	1.48
Dec 25	1.53
Nov 25	1.53
Nov 25	1.48
Nov 25	1.62
Nov 25	0.63
Oct 25	0.67
Oct 25	0.68
Oct 25	0.68
Oct 25	0.72
Oct 25	0.76
Sep 25	0.65
Sep 25	0.67
Sep 25	0.67
Sep 25	0.67
Aug 25	0.72
Aug 25	0.72
Aug 25	0.74
Aug 25	3.32
Aug 25	4.02
Jul 25	4.46
Jul 25	3.93
Jul 25	3.41
Jul 25	2.88
Jun 25	2.97
Jun 25	2.19
Jun 25	3.06
Jun 25	4.98
May 25	6.03
May 25	6.03
May 25	5.77
May 25	2.74
May 25	3.06
Apr 25	3.15
Apr 25	3.15
Apr 25	3.24
Apr 25	2.88
Mar 25	3.06
Mar 25	3.38
Mar 25	3.15
Mar 25	3.43
Feb 25	0.78
Feb 25	0.78
Feb 25	0.73
Feb 25	0.76
Jan 25	0.82
Jan 25	0.97
Jan 25	0.95
Jan 25	1.01
Jan 25	1.08
Dec 24	1.01
Dec 24	1.06
Dec 24	1.08
Dec 24	1.19
Nov 24	0.99
Nov 24	1
Nov 24	1.05
Nov 24	1.02
Nov 24	0.99
Oct 24	1.08
Oct 24	0.99

No video analysis for this stock yet. Request one from our team.

News: ADIL

globenewswire.com · 25 Aug 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company.

globenewswire.com · 17 Aug 2026

Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update

Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline

globenewswire.com · 16 Jun 2026

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026.